Bruton’s酪氨酸激酶抑制剂Ibrutinib与B细胞肿瘤

基础医学与临床 ›› 2014, Vol. 34 ›› Issue (9): 1281-1284.

Bruton’s酪氨酸激酶抑制剂Ibrutinib与B细胞肿瘤

顾立超¹,王报春²,陈乃耀¹

1. 河北联合大学附属医院
2. 中国医学科学院血液学研究所贫血中心

收稿日期:2013-10-21 修回日期:2013-12-20 出版日期:2014-09-05 发布日期:2014-09-02
通讯作者: 陈乃耀 E-mail:nychenncmc@163.com
基金资助:
《白藜芦醇促进基于间充质干细胞的骨修复作用及机制》

Bruton’s Tyrosine Kinase inhibitor Ibrutinib and B-cell malignancy

Received:2013-10-21 Revised:2013-12-20 Online:2014-09-05 Published:2014-09-02

摘要/Abstract

摘要： 酪氨酸激酶的过度激活，导致其下游信号途径的激活，最终导致细胞的转化、增殖和抵抗细胞凋亡、促进细胞生存。因此，许多学者致力于一些与肿瘤细胞分化增殖相关的细胞信号转导通路的关键酶作为药物筛选靶点，证实选择性作用于特定靶点的高效新型抗癌药物-Bruton’s酪氨酸激酶抑制剂Ibrutinib在初步抗B细胞肿瘤临床试验中具有非常好的疗效。

关键词: Bruton’s酪氨酸激酶, Ibrutinib, B细胞肿瘤

Abstract: Excessive activation of Burton’s tyrosine kinase (BTK) resulted in transduction of downstream signaling pathways, which led to transformation and proliferation of B cell tumors to resist apoptosis and promote cell survival. Therefore, many researchers devoted to explore key BTK inhibitors against tumor cell proliferation-related cellular signal transduction pathway. Ibrutinib has been identified as a candidated drug with efficiency on specific target –BTK. So far, ibrutinib as a Bruton's tyrosine kinase inhibitor has become an important drug against B-cell tumor drugs and the patients with B-cell tumors showed quite good response to ibrutinib in the preliminary clinical trials.

Key words: Bruton’s Tyrosine Kinase , Ibrutinib, B-cell malignancy

顾立超王报春陈乃耀. Bruton’s酪氨酸激酶抑制剂Ibrutinib与B细胞肿瘤[J]. 基础医学与临床, 2014, 34(9): 1281-1284.